American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

Autor: Pieter Sonneveld, Sagar Lonial, Sergio Giralt, Henk M. Lokhorst, Christina Gasparreto, Raymond L. Comenzo, Jenny Bird, Bart Barlogie, Amitabha Mazumder, Shaji Kumar, Brian G.M. Durie, Hans Erik Johnsen, Edward A. Stadtmauer, Paul G. Richardson, Muzaffer Qazilbash, Saad Z. Usmani, Gösta Gahrton, Heinz Ludwig, William I. Bensinger, P. Moreau, Paremesweran Hari, Charles F. LeMaistre, David H. Vesole, H. Goldschmidt, Amrita Krishnan, Gordon Cook, Vincent Rajkumar, Antonio Palumbo, Hareth Nahi, Jin Lu, Maria V. Mateos, Michele Cavo, Joan Bladé, Javier de la Rubia, Jesús F. San Miguel, Sundar Jagannath, Christopher Bredeson, Meletios A. Dimopoulos, Ramón García-Sanz, Robert A. Kyle, Joseph R. Mikhael, P.L. McCarthy, Rafat Abonour, Yvonne A. Efebera, Eloisa Riva, M. Mohty, Robert Z. Orlowski, Douglas E. Joshua, Benedetto Bruno, Anil Nooka, Laurent Garderet, Marcelo C. Pasquini, Peter Gimsing, Ingemar Turreson, Sarah A. Holstein, Anthony Reiman, Guenther Koehne, Michel Attal, James Gajewski, Hermann Einsele, Jens Hillengass, Nicolaus Kroeger, Xavier Leleu, Kenneth C. Anderson, Orhan Sezer
Přispěvatelé: Hematology, Radiology & Nuclear Medicine, Sergio, Giralt, Laurent, Garderet, Brian, Durie, Gordon, Cook, Gosta, Gahrton, Benedetto, Bruno, Paremesweran, Hari, Henk, Lokhorst, Phillip, Mccarthy, Amrita, Krishnan, Pieter, Sonneveld, Harmut, Goldschmidt, Sundar, Jagannath, Bart, Barlogie, Maria, Mateo, Peter, Gimsing, Orhan, Sezer, Joseph, Mikhael, Jin, Lu, Meletios, Dimopoulo, Amitabha, Mazumder, Antonio, Palumbo, Rafat, Abonour, Kenneth, Anderson, Michel, Attal, Joan, Blade, Jenny, Bird, Michele, Cavo, Raymond, Comenzo, Javier de la Rubia, Hermann, Einsele, Ramon, Garcia-Sanz, Jens, Hillenga, Sarah, Holstein, Hans Erik Johnsen, Douglas, Joshua, Guenther, Koehne, Shaji, Kumar, Robert, Kyle, Xavier, Leleu, Sagar, Lonial, Heinz, Ludwig, Hareth, Nahi, Anil, Nooka, Robert, Orlowski, Vincent, Rajkumar, Anthony, Reiman, Paul, Richardson, Eloisa, Riva, Jesus San Miguel, Ingemar, Turreson, Saad, Usmani, David, Vesole, William, Bensinger, Muzaffer, Qazilbash, Yvonne, Efebera, Mohamed, Mohty, Christina, Gasparreto, James, Gajewski, Lemaistre, Charles F., Chris, Bredeson, Phillipe, Moreau, Marcelo, Pasquini, Nicolaus, Kroeger, Edward, Stadtmauer
Rok vydání: 2015
Předmět:
Oncology
medicine.medical_specialty
Transplantation Conditioning
medicine.medical_treatment
Salvage therapy
Myeloma
Hematopoietic stem cell transplantation
Transplantation
Autologous
Article
03 medical and health sciences
0302 clinical medicine
Maintenance therapy
immune system diseases
Recurrence
Internal medicine
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Immunologic Factors
Transplantation
Homologous
Multiple myeloma
Bone Marrow Transplantation
Randomized Controlled Trials as Topic
Salvage Therapy
Transplantation
Stem cell transplantation
Hematology
business.industry
Remission Induction
Hematopoietic Stem Cell Transplantation
Antibodies
Monoclonal
Myeloablative Agonists
medicine.disease
3. Good health
Surgery
Clinical trial
surgical procedures
operative
030220 oncology & carcinogenesis
business
Multiple Myeloma
Proteasome Inhibitors
030215 immunology
Zdroj: Biology of Blood and Marrow Transplantation, 21(12), 2039-2051. Elsevier Inc.
Giralt, S, Garderet, L, Durie, B, Cook, G, Gahrton, G, Bruno, B, Hari, P, Lokhorst, H, McCarthy, P, Krishnan, A, Sonneveld, P, Goldschmidt, H, Jagannath, S, Barlogie, B, Mateos, M, Gimsing, P, Sezer, O, Mikhael, J, Jin, L, Dimopoulos, M, Mazumder, A, Palumbo, A, Abonour, R, Anderson, K, Attal, M, Blade, J, Bird, J, Cavo, M, Comenzo, R, de la Rubia, J, Einsele, H, Garcia Sanz, R, Hillengass, J, Holstein, S, Johnsen, H E, Joshua, D, Koehne, G, Kumar, S, Kyle, R, Leleu, X, Lonial, S, Ludwig, H, Nahi, H, Nooka, A, Orlowski, R, Rajkumar, V, Reiman, A, Richardson, P, Rivas, E, San Miguel, J, Turreson, I, Usmani, S, Vesole, D, Bensinger, W, Qazilbash, M, Efebera, Y, Mohty, M, Gasparreto, C, Gajewski, J, LeMaistre, C, Bredeson, C, Moreau, P, Pasquini, M, Kroeger, N & Stadtmauer, E 2015, ' American Society of Blood and Marrow Transplant, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma ', Biology of Blood and Marrow Transplantation, vol. 21, no. 12, pp. 2039-2051 . https://doi.org/10.1016/j.bbmt.2015.09.016
ISSN: 1523-6536
1083-8791
DOI: 10.1016/j.bbmt.2015.09.016
Popis: In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with multiple myeloma (MM) is well established, the role of high-dose therapy with autologous or allogeneic HCT has not been extensively studied in MM patients relapsing after primary therapy. The International Myeloma Working Group together with the Blood and Marrow Transplant Clinical Trials Network, the American Society of Blood and Marrow Transplantation, and the European Society of Blood and Marrow Transplantation convened a meeting of MM experts to: (1) summarize current knowledge regarding the role of autologous or allogeneic HCT in MM patients progressing after primary therapy, (2) propose guidelines for the use of salvage HCT in MM, (3) identify knowledge gaps, (4) propose a research agenda, and (5) develop a collaborative initiative to move the research agenda forward. After reviewing the available data, the expert committee came to the following consensus statement for salvage autologous HCT: (1) In transplantation-eligible patients relapsing after primary therapy that did NOT include an autologous HCT, high-dose therapy with HCT as part of salvage therapy should be considered standard; (2) High-dose therapy and autologous HCT should be considered appropriate therapy for any patients relapsing after primary therapy that includes an autologous HCT with initial remission duration of more than 18 months; (3) High-dose therapy and autologous HCT can be used as a bridging strategy to allogeneic HCT; (4) The role of postsalvage HCT maintenance needs to be explored in the context of well-designed prospective trials that should include new agents, such as monoclonal antibodies, immune-modulating agents, and oral proteasome inhibitors; (5) Autologous Ha consolidation should be explored as a strategy to develop novel conditioning regimens or post-HCT strategies in patients with short (less than 18 months remissions) after primary therapy; and (6) Prospective randomized trials need to be performed to define the role of salvage autologous HCT in patients with MM relapsing after primary therapy comparing it to "best non-HCT therapy. The expert committee also underscored the importance of collecting enough hematopoietic stem cells to perform 2 transplantations early in the course of the disease. Regarding allogeneic Ha, the expert committee agreed on the following consensus statements: (1) Allogeneic HCT should be considered appropriate therapy for any eligible patient with early relapse (less than 24 months) after primary therapy that included an autologous HCT and/or high-risk features (ie, cytogenetics, extramedullary disease, plasma cell leukemia, or high lactate dehydrogenase); (2) Allogeneic HCT should be performed in the context of a clinical trial if possible; (3) The role of postallogeneic Ha maintenance therapy needs to be explored in the context of well-designed prospective trials; and (4) Prospective randomized trials need to be performed to define the role salvage allogeneic HCT in patients with MM relapsing after primary therapy. (c) 2015 American Society for Blood and Marrow Transplantation.
Databáze: OpenAIRE
Externí odkaz: